Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.42 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TTK | P33981 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3114886 | 0.95 | RAB9A (0.41) | RAB9ANPC1SMN1; SMN2MAPK14RXFP1 | |
| SCHEMBL3102917 | 0.94 | MAPK14 (0.40) | RAB9ANPC1SMN1; SMN2MAPK14RXFP1 | |
| SCHEMBL3112608 | 0.94 | NPC1 (0.48) | RAB9ANPC1SMN1; SMN2MAPK14HPGD | |
| SCHEMBL3105220 | 0.93 | RAB9A (0.46) | RAB9ANPC1SMN1; SMN2RXFP1HSD11B1 | |
| SCHEMBL3110664 | 0.93 | MAPK14 (0.47) | RAB9ANPC1SMN1; SMN2MAPK14KMT2A | |
| SCHEMBL3117690 | 0.92 | MAPK14 (0.46) | SMN1; SMN2MAPK14RXFP1MAPTKMT2A | |
| SCHEMBL3110448 | 0.90 | PLK1 (0.42) | RAB9ARXFP1HSD11B1MAPTROCK1 | |
| SCHEMBL3109046 | 0.90 | KMT2A (0.51) | RAB9ANPC1SMN1; SMN2RXFP1HSD11B1 | |
| SCHEMBL3107080 | 0.90 | RAB9A (0.48) | RAB9ANPC1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL3110919 | 0.90 | MAPK14 (0.45) | MAPK14RXFP1HSD11B1MAPK11KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803822-B2 | Triazole derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-28 | — | — | US | disclosed |
| US-20090105253-A1 | Triazole Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-23 | — | — | US | disclosed |
| EP-1867331-A1 | TRIAZOLE DERIVATIVE AND THE USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105253-A1 | Triazole Derivative and Use Thereof | F2R, HRH4, F2RL3 | CHRNA10 1085/4885CHRNA9 707/4885RAB9A 2959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.